The latest price target for Pliant Therapeutics (NASDAQ:PLRX) was reported by HC Wainwright & Co. on November 8, 2024. The analyst firm set a price target for $38.00 expecting PLRX to rise to within 12 months (a possible 187.65% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Pliant Therapeutics (NASDAQ:PLRX) was provided by HC Wainwright & Co., and Pliant Therapeutics reiterated their buy rating.

There is no last upgrade for Pliant Therapeutics

There is no last downgrade for Pliant Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pliant Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pliant Therapeutics was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

While ratings are subjective and will change, the latest Pliant Therapeutics (PLRX) rating was a reiterated with a price target of $38.00 to $38.00. The current price Pliant Therapeutics (PLRX) is trading at is $13.21, which is out of the analyst’s predicted range.